Interleukin‐6 dependence of advanced malignant plasma cell dyscrasias
Interleukin‐6 dependence of advanced malignant plasma cell dyscrasias
复制标题
晚期恶性浆细胞恶液质的 IL-6 依赖性
作者：
Xue Zhang;R. Bataille;J. Widjenes;B. Klein
作者和其他人明确证实白介素-6 (IL-6) 是体外人骨髓瘤细胞的主要生长因子。 IL-6 是否仍然参与恶性浆细胞恶液质疾病进展的最后阶段是一个关键的概念点。为了回答这个问题，作者评估了来自 13 名晚期多发性骨髓瘤 (MM) 患者骨髓和 13 名浆细胞白血病患者（7 例原发性病例和 6 例继发性病例）外周血的骨髓瘤细胞增殖的体外 IL-6 依赖性。他们的结果表明，26 名患者中有 25 名的骨髓瘤细胞生长完全依赖于 IL-6。只有一名患者的骨髓瘤细胞在体外对 IL-6 没有反应。事实上，这位患者的细胞在体内并没有增殖。在四名 PCL 患者的外周血和骨髓中发现了相同的骨髓瘤细胞 IL-6 依赖性模式。作者得出的结论是，在恶性浆细胞恶液质的终末期，体外肿瘤生长完全依赖于 IL-6。这一观察结果对于考虑晚期 MM 患者的抗 IL-6 治疗研究至关重要。癌症1992； 69：1373-1376。
The authors, and others, clearly have established that interleukin‐6 (IL‐6) is the major growth factor for human myeloma cells in vitro. It is a critical conceptual point whether or not IL‐6 remains involved in the final phases of disease progression in malignant plasma cell dyscrasias. To answer this question, the authors evaluated the in vitro IL‐6 dependence of the proliferation of myeloma cells from the bone marrow of 13 patients with advanced multiple myeloma (MM) and from the peripheral blood of 13 patients with plasma cell leukemia (seven primary and six secondary cases). Their results show that myeloma cell growth was totally dependent on IL‐6 in 25 of 26 patients. Myeloma cells of only one patient did not respond to IL‐6 in vitro. Actually, the cells from this patient were not proliferating in vivo. Identical patterns of IL‐6 dependence of myeloma cells were found in the peripheral blood and bone marrow from four patients with PCL. The authors conclude that, in the terminal phase of malignant plasma cell dyscrasias, tumoral growth is totally dependent on IL‐6 in vitro. This observation is critical in considering the investigation of anti‐IL‐6 therapy in patients with advanced MM. Cancer 1992; 69:1373‐1376.